- Home
- BRT vs TNGX Comparison
BRT vs TNGX Comparison
Compare BRT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- TNGX
- Stock Information
- Founded
- BRT 1972
- TNGX 2014
- Country
- BRT United States
- TNGX United States
- Employees
- BRT N/A
- TNGX N/A
- Industry
- BRT Real Estate Investment Trusts
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- TNGX Health Care
- Exchange
- BRT Nasdaq
- TNGX Nasdaq
- Market Cap
- BRT 331.7M
- TNGX 317.4M
- IPO Year
- BRT N/A
- TNGX N/A
- Fundamental
- Price
- BRT $18.16
- TNGX $1.76
- Analyst Decision
- BRT Strong Buy
- TNGX Strong Buy
- Analyst Count
- BRT 3
- TNGX 7
- Target Price
- BRT $22.17
- TNGX $12.33
- AVG Volume (30 Days)
- BRT 23.1K
- TNGX 801.9K
- Earning Date
- BRT 05-07-2025
- TNGX 05-07-2025
- Dividend Yield
- BRT 5.60%
- TNGX N/A
- EPS Growth
- BRT N/A
- TNGX N/A
- EPS
- BRT N/A
- TNGX N/A
- Revenue
- BRT $97,274,000.00
- TNGX $42,069,000.00
- Revenue This Year
- BRT N/A
- TNGX N/A
- Revenue Next Year
- BRT $5.39
- TNGX N/A
- P/E Ratio
- BRT N/A
- TNGX N/A
- Revenue Growth
- BRT 1.65
- TNGX 15.17
- 52 Week Low
- BRT $15.81
- TNGX $1.71
- 52 Week High
- BRT $20.22
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- BRT 53.99
- TNGX 33.97
- Support Level
- BRT $17.30
- TNGX $1.80
- Resistance Level
- BRT $18.50
- TNGX $2.04
- Average True Range (ATR)
- BRT 0.64
- TNGX 0.18
- MACD
- BRT 0.02
- TNGX 0.01
- Stochastic Oscillator
- BRT 50.29
- TNGX 20.19
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.